Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $1.2 million.

  • Fulcrum Therapeutics' Other Non-Current Assets changed negligibly% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.2 million for FY2024, which is 40.28% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Other Non-Current Assets stood at $1.2 million for Q3 2025, which was down 0.33% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Other Non-Current Assets ranged from a high of $2.1 million in Q4 2022 and a low of $1.1 million during Q1 2021.
  • For the 3-year period, Fulcrum Therapeutics' Other Non-Current Assets averaged around $1.2 million, with its median value being $1.2 million (2025).
  • Per our database at Business Quant, Fulcrum Therapeutics' Other Non-Current Assets soared by 92.77% in 2022 and then slumped by 40.28% in 2024.
  • Fulcrum Therapeutics' Other Non-Current Assets (Quarterly) stood at $1.1 million in 2021, then skyrocketed by 92.77% to $2.1 million in 2022, then fell by 4.47% to $2.0 million in 2023, then plummeted by 40.28% to $1.2 million in 2024, then remained steady at $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.